Bio-path Announced The Completion Of The First Dose Cohort Of The Dose Escalation Portion Of Its Phase 1/1b Clinical Trial Of BP1001-A (Liposomal Grb2) In Patients With Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings, Inc. (BPTH) has completed the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1001-A (Liposomal Grb2) in patients with solid tumors.

July 17, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path's completion of the first dose cohort of its Phase 1/1b clinical trial could potentially lead to positive outcomes for the company's drug development process.
The completion of the first dose cohort of the dose escalation portion of the Phase 1/1b clinical trial is a significant milestone in the drug development process. This could potentially lead to positive outcomes for the company's drug development process, which could in turn have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100